Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:34:23 EDT Wed 16 Sep 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:FHTX - FOGHORN THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FHTX - Q0.14.16·4.170.34.165+0.0451.160.41981,0024.17  4.23  4.087.61  3.2712:18:00Aug 0615 min RT 2¢

Recent Trades - Last 10 of 1002
Time ETExPriceChangeVolume
12:18:00Q4.1650.0453
12:17:51Q4.16290.04295
12:17:41Q4.1650.0453
12:17:41Q4.16480.04486
12:17:31Q4.1650.0455
12:17:16Q4.160.045
12:17:11Q4.1650.045100
12:17:05Q4.1650.0453
12:16:54Q4.1650.0455
12:16:44Q4.160.0427

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-08-06 07:00U:FHTXNews ReleaseFoghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
2026-06-05 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
2026-05-12 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
2026-05-07 07:00U:FHTXNews ReleaseFoghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
2026-04-21 16:05U:FHTXNews ReleaseFoghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
2026-04-09 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
2026-03-11 16:10U:FHTXNews ReleaseFoghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
2026-02-24 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Participate in Two Upcoming Investor Conferences
2026-02-23 07:00U:FHTXNews ReleaseFoghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
2026-02-03 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
2026-01-13 16:05U:FHTXNews ReleaseFoghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
2026-01-09 22:20U:FHTXNews ReleaseFoghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
2025-11-25 07:00U:FHTXNews ReleaseFoghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-05 07:00U:FHTXNews ReleaseFoghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
2025-11-03 07:30U:FHTXNews ReleaseFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences
2025-10-30 07:30U:FHTXNews ReleaseFoghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
2025-10-16 07:00U:FHTXNews ReleaseFoghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit